BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 23403252)

  • 21. Two molecular subgroups of Wilms' tumors with or without WT1 mutations.
    Schumacher V; Schuhen S; Sonner S; Weirich A; Leuschner I; Harms D; Licht J; Roberts S; Royer-Pokora B
    Clin Cancer Res; 2003 Jun; 9(6):2005-14. PubMed ID: 12796362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of Wilms' tumor genes.
    Hirose M
    J Med Invest; 1999 Aug; 46(3-4):130-40. PubMed ID: 10687307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The novel WT1 gene mutation p.H377N associated to Denys-Drash syndrome.
    Guaragna MS; Soardi FC; Assumpção JG; Zambaldi Lde J; Cardinalli IA; Yunes JA; de Mello MP; Brandalise SR; Aguiar Sdos S
    J Pediatr Hematol Oncol; 2010 Aug; 32(6):486-8. PubMed ID: 20562648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The same mutation affecting the splicing of WT1 gene is present on Frasier syndrome patients with or without Wilms' tumor.
    Barbosa AS; Hadjiathanasiou CG; Theodoridis C; Papathanasiou A; Tar A; Merksz M; Györvári B; Sultan C; Dumas R; Jaubert F; Niaudet P; Moreira-Filho CA; Cotinot C; Fellous M
    Hum Mutat; 1999; 13(2):146-53. PubMed ID: 10094551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exclusion of the Wilms tumour gene (WT1) promoter as a site of frequent mutation in Wilms tumour.
    Grubb GR; Yun K; Reeve AE; Eccles MR
    Oncogene; 1995 Apr; 10(8):1677-81. PubMed ID: 7731725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Germline WT1 mutations in Wilms' tumor patients: preliminary results.
    Li FP; Breslow NE; Morgan JM; Ghahremani M; Miller GA; Grundy PE; Green DM; Diller LR; Pelletier J
    Med Pediatr Oncol; 1996 Nov; 27(5):404-7. PubMed ID: 8827066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutations of the p53 tumor suppressor gene occur infrequently in Wilms' tumor.
    Malkin D; Sexsmith E; Yeger H; Williams BR; Coppes MJ
    Cancer Res; 1994 Apr; 54(8):2077-9. PubMed ID: 8174107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.
    Borel F; Barilla KC; Hamilton TB; Iskandar M; Romaniuk PJ
    Biochemistry; 1996 Sep; 35(37):12070-6. PubMed ID: 8810912
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel familial WT1 read-through mutation associated with Wilms tumor and slow progressive nephropathy.
    Zirn B; Wittmann S; Gessler M
    Am J Kidney Dis; 2005 Jun; 45(6):1100-4. PubMed ID: 15957141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel frame shift mutations ('A' deletion) observed in exon 9 of Wilms' tumor (WT1) gene in a patient reported with glomerulosclerosis.
    Pasupuleti SK; Katari V; Lokanathan S; Uppu VP; Thummaginjala SS; Akkamgari RP; Ayapati T; Kottu R; Potukuchi VG
    Gene; 2014 Aug; 546(1):63-7. PubMed ID: 24853201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies.
    Fukuzawa R; Heathcott RW; More HE; Reeve AE
    J Clin Pathol; 2007 Sep; 60(9):1013-6. PubMed ID: 17172473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inherited WT1 mutation in Denys-Drash syndrome.
    Coppes MJ; Liefers GJ; Higuchi M; Zinn AB; Balfe JW; Williams BR
    Cancer Res; 1992 Nov; 52(21):6125-8. PubMed ID: 1327525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour.
    Pelletier J; Bruening W; Li FP; Haber DA; Glaser T; Housman DE
    Nature; 1991 Oct; 353(6343):431-4. PubMed ID: 1654525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour.
    Park S; Bernard A; Bove KE; Sens DA; Hazen-Martin DJ; Garvin AJ; Haber DA
    Nat Genet; 1993 Dec; 5(4):363-7. PubMed ID: 8298644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. WT1: a novel tumor suppressor gene inactivated in Wilms' tumor.
    Haber DA; Buckler AJ
    New Biol; 1992 Feb; 4(2):97-106. PubMed ID: 1313285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Topotecan distribution in an anephric infant with therapy-resistant bilateral Wilms tumor with a novel germline WT1 gene mutation.
    Lugtenberg RT; Cransberg K; Loos WJ; Wagner A; Alders M; van den Heuvel-Eibrink MM
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1039-44. PubMed ID: 18273617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A point mutation within exon 5 of the WT1 gene of a sporadic unilateral Wilms' tumor alters gene function.
    Guan LS; Liu JJ; Xu YH; Wang ZY
    Cancer Res; 1998 Sep; 58(18):4180-4. PubMed ID: 9751632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Surgical management and genotype/phenotype correlations in WT1 gene-related diseases (Drash, Frasier syndromes).
    Auber F; Lortat-Jacob S; Sarnacki S; Jaubert F; Salomon R; Thibaud E; Jeanpierre C; Nihoul-Fékété C
    J Pediatr Surg; 2003 Jan; 38(1):124-9; discussion 124-9. PubMed ID: 12592634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spectrum of early onset nephrotic syndrome associated with WT1 missense mutations.
    Schumacher V; Schärer K; Wühl E; Altrogge H; Bonzel KE; Guschmann M; Neuhaus TJ; Pollastro RM; Kuwertz-Bröking E; Bulla M; Tondera AM; Mundel P; Helmchen U; Waldherr R; Weirich A; Royer-Pokora B
    Kidney Int; 1998 Jun; 53(6):1594-600. PubMed ID: 9607189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. WTX inactivation is a frequent, but late event in Wilms tumors without apparent clinical impact.
    Wegert J; Wittmann S; Leuschner I; Geissinger E; Graf N; Gessler M
    Genes Chromosomes Cancer; 2009 Dec; 48(12):1102-11. PubMed ID: 19760609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.